Lansoprazol Genericon

Lansoprazole, the active ingredient in Lansoprazol Genericon, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is indicated for conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, Zollinger‑Ellison syndrome, and Helicobacter pylori eradication regimens, primarily in adult patients.

GNH USA supplies Lansoprazol Genericon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides batch‑tested product for global distribution.

Lansoprazole is used to treat acid‑related gastrointestinal disorders by decreasing gastric acid production. - Gastroesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal erosion. - Peptic ulcer disease: facilitates ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors. - Helicobacter pylori eradication therapy: used as part of combination regimens to improve bacterial eradication rates.

Lansoprazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Nausea: occasional feeling of queasiness. - Abdominal pain: discomfort or cramping in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, rash, difficulty breathing. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Hepatic enzyme elevation: increased ALT/AST indicating liver stress. - Hypomagnesemia: low serum magnesium leading to muscle cramps or arrhythmia. - Stevens‑Johnson syndrome: serious skin and mucous membrane disorder. - Interstitial nephritis: kidney inflammation causing reduced function.

Before prescribing Lansoprazole, clinicians should consider several safety precautions. - Assess renal function: adjust use in patients with severe renal impairment. - Monitor for drug interactions: review concomitant medications that may affect acid suppression. - Use lowest effective dose: limit duration to the shortest period necessary. - Avoid abrupt discontinuation: taper to prevent rebound acid hypersecretion. - Caution in elderly: increased susceptibility to electrolyte disturbances. - Store at room temperature: keep in the original container, protect from moisture.

Lansoprazole can alter the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clarithromycin: may increase lansoprazole levels, raising risk of toxicity. - Atazanavir: reduced absorption of atazanavir leading to therapeutic failure.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in anticoagulant effect, monitor INR. - Methotrexate: decreased renal clearance may raise toxicity, check serum levels. - Digoxin: possible increase in serum digoxin, observe for signs of toxicity. - Phenytoin: reduced phenytoin levels may decrease seizure control. - Ciclosporin: increased levels may cause nephrotoxicity.